scholarly journals Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis

2021 ◽  
Vol 25 ◽  
pp. 101214
Author(s):  
Zhaoyu Wu ◽  
Zhijue Xu ◽  
Hongji Pu ◽  
Weimin Li ◽  
Junchao Liu ◽  
...  
Keyword(s):  
2012 ◽  
Vol 03 (04) ◽  
pp. 184-185
Author(s):  
Christine Vetter
Keyword(s):  

Die „Targeted Therapy” hat in den vergangenen Jahren in vielen Bereichen der Onkologie Fuß gefasst und gewinnt auch beim Lungenkarzinom zunehmend an Boden. Wie sich diese neue Therapierichtung künftig entwickeln kann, war eines der Themen beim diesjährigen Deutschen Krebskongress in Berlin.


2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.


2015 ◽  
Author(s):  
Paul Lennon ◽  
Sandra Deady ◽  
Marie-Louise Healy ◽  
John Kinsella ◽  
Conrad Timon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document